市場調查報告書

全球結膜炎治療市場:成長,趨勢,及預測

Conjunctivitis Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921946
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球結膜炎治療市場:成長,趨勢,及預測 Conjunctivitis Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球結膜炎治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各疾病類型·製劑類型·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 患有結膜炎的人數增加
    • 容易獲得治療
  • 市場阻礙因素
    • 是否提供其他替代療法,例如家庭療法
  • 波特的五力分析

第5章 市場區隔

  • 各疾病類型
    • 過敏性結膜炎
    • 細菌性結膜炎
    • 病毒性結膜炎
  • 各製劑類型
    • 軟膏
    • 眼科用藥
    • 藥物
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Novartis AG
    • Bausch & Lomb Incorporated
    • Allergan Plc
    • NicOx SA
    • Alembic Pharmaceuticals
    • Sanofi SA
    • Pfizer Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 67343

Market Overview

The market studied is expected to grow in the forecast period due to the high number of people suffering from allergic conjunctivitis and the easier availability of the treatment across the globe.

The National Institute of Health has stated in its 2017 report that the prevalence of conjunctivitis is around 6-30% in the general population and up to 30% in the children across the globe. As the disease is very common, treatment for the same is easily available. Most of the time, the disease is self diagnosable and there is the least need of undergoing any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. As per the article published by a journal named Clinical Epidemiology and Global Health, it was found that during the year 2019, the prevalence of allergic conjunctivitis was around 12.22% and the number of men suffering from this disease is higher than that of females in India. The epidemiology of the disease is similar in other Asian countries such as China.

Hence, owing to the high prevalence of the disease, the market studied is expected to have a steady growth over the forecast period.

Scope of the Report

As per the scope of the report, conjunctivitis is an irritation or inflammation of the conjunctiva. The scope of the report includes the type of conjunctivitis and its geographical scenario.

Key Market Trends

Allergic Conjunctivitis is Expected to Witness a Steady Growth

The allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. The people having allergies are more likely to develop allergic conjunctivitis. As stated by the Asthma and Allergy Foundation of America, approximately 30% of the adults and 40% of the children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust.

Treatment for acute conjunctivitis includes oral or over the counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available in the market easily which are found to provide relief in acute conjunctivitis. Hence, this segment will witness steady growth during the forecast period.

The United States Dominate the Market

It has been stated by the National Institue of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the near future.

Competitive Landscape

The market for conjunctivitis treatment includes international as well as local companies. The disease is self diagnosable and does not always need hospitalization. Therefore, people rely on home remedies or over the counter drugs for treatment. The local companies across various countries are doing a good business in this market as the cost of the drug is less and the preference of people about OTC is increasing.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of People Suffering From Conjunctivitis
    • 4.2.2 Easy Availability of the Treatment
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments Such as Home Remedies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Allergic Conjunctivitis
    • 5.1.2 Bacterial Conjunctivitis
    • 5.1.3 Viral Conjunctivitis
  • 5.2 By Formulation Type
    • 5.2.1 Ointment
    • 5.2.2 Drops
    • 5.2.3 Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Bausch & Lomb Incorporated
    • 6.1.3 Allergan Plc
    • 6.1.4 NicOx S.A.
    • 6.1.5 Alembic Pharmaceuticals
    • 6.1.6 Sanofi S.A.
    • 6.1.7 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS